Israeli Studies Highlight Potential of Hyperbaric Oxygen Therapy in Aging Research
Hyperbaric oxygen therapy (HBOT), traditionally used for conditions like decompression sickness and carbon monoxide poisoning, is gaining attention in longevity medicine due to Israeli research suggesting it may influence biological markers of aging. Studies conducted at the Sagol Center for Hyperbaric Medicine at Shamir Medical Center (Assaf Harofeh) have reported changes in telomere length and reductions in senescent cells among healthy adults aged 64 and older after undergoing 60 HBOT sessions over three months. These findings indicate potential cellular rejuvenation effects but do not yet prove that HBOT extends lifespan or reduces age-related disease risk.
Additional Israeli research has explored HBOT’s impact on brain health, showing improved cerebral blood flow and cognitive test performance in individuals with mild cognitive decline or brain injury. A double-blind study published in 2025 also found changes in brain imaging and cognitive function metrics. However, experts emphasize that larger, long-term studies are needed to confirm any clinically significant benefits.
HBOT involves breathing pure oxygen at about twice atmospheric pressure inside a sealed chamber, increasing oxygen dissolved in the blood and enhancing delivery to tissues with limited blood flow. This process may stimulate new blood vessel formation, mitochondrial activity, stem cell recruitment, and tissue repair.
Despite promising preliminary results, HBOT is not yet approved for anti-aging purposes and should not be considered a substitute for healthy lifestyle practices such as exercise, Mediterranean diet, quality sleep, and chronic disease management. Currently, HBOT remains an established treatment only for specific medical conditions like decompression sickness, carbon monoxide poisoning, diabetic foot ulcers, radiation injuries, certain infections, and chronic wounds.
In summary, while HBOT is one of the most promising areas in longevity research, Israeli studies highlight encouraging biological changes without definitive proof of slowed clinical aging or extended lifespan. Experts advise cautious optimism and await further rigorous research to clarify HBOT’s role in aging and brain health.
